Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 5/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31248139 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL31257872 | 0.92 | SMN1; SMN2 (0.42) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL2010697 | 0.87 | RAB9A (0.49) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL10337042 | 0.80 | MAPT (0.64) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL31627182 | 0.77 | RAB9A (0.48) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL10557663 | 0.76 | MAPT (0.69) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL20492122 | 0.76 | TDP1 (0.65) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL28453669 | 0.76 | RAB9A (0.55) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL29739813 | 0.76 | RAB9A (0.55) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL25983659 | 0.76 | TDP1 (0.55) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-8420669-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor | LABORATORIES ALMIRALL, S.A. (ES) | 2013-04-16 | — | — | US | disclosed |
| WO-2013050375-A1 | PROCESS FOR PREPARING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | WO | disclosed |
| US-8242177-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2012-08-14 | — | — | US | disclosed |
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-05-10 | — | — | US | disclosed |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | US | disclosed |
| EP-1885684-B9 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-20110251165-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. | 2011-10-13 | — | — | US | disclosed |
| EP-1885684-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-07-13 | — | — | EP | disclosed |
| US-7964615-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| EP-2263998-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor | Almirall S.A. (ES) | 2010-12-22 | — | — | EP | disclosed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | UGT1A8, UGT1A1, UGT8 | SMN1; SMN2 1434/4885TDP1 2092/4885L3MBTL1 4841/4885 |
| US-20110251165-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB3 | SMN1; SMN2 3832/4885TDP1 4721/4885L3MBTL1 3439/4885 |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ADRB2, ADRA2C, ADRB1 | SMN1; SMN2 3113/4885TDP1 4691/4885L3MBTL1 3262/4885 |
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | ADRB2, ADRB1, ADRA2C | SMN1; SMN2 3260/4885TDP1 2844/4885L3MBTL1 4438/4885 |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | ADRB2, ADRB1, ADRA2C | SMN1; SMN2 3622/4885TDP1 2848/4885L3MBTL1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.